Association study between the PIK4CA gene and methamphetamine use disorder in a japanese population

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 150, Issue 2, 2009, Pages 233-238

  Kanahara, Nobuhisa ^a   Miyatake, Ryosuke ^a   Sekine, Yoshimoto ^b,c   Inada, Toshiya ^c,d   Ozaki, Norio ^c,e   Iwata, Nakao ^c,f   Harano, Mutsuo ^c,g   Komiyama, Tokutaro ^c,h   Yamada, Mitsuhiko ^c,h   Sora, Ichiro ^c,i   Ujike, Hiroshi ^c,j   Iyo, Masaomi ^a,c   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Japanese Genetics Initiative for Drug Abuse (JGIDA)   (Japan)

^d SEIWA HOSPITAL   (Japan)

^e NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

ⁱ TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j OKAYAMA UNIVERSITY   (Japan)

more..

Author keywords

Case Control study; Methamphetamine; PIK4CA; Psychosis

Indexed keywords

METHAMPHETAMINE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG ABUSE; DRUG DEPENDENCE; FEMALE; GENE; GENE LOCATION; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PIK4CA GENE; PRIORITY JOURNAL; PSYCHOSIS; RECURRENT DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ALLELES; AMPHETAMINE-RELATED DISORDERS; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PSYCHOTIC DISORDERS;

EID: 61449245571     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30797     Document Type: Article

References (37)

1. Bakker SC, Hoodendoorn ML, Hendriks J, Verzijlbergen K, Caron S, et al. 2007. PIP5K2A and RGS4 genes are differentially associated with deficit and non-deficit schizophrenia. Genes Brain Behav 10:113-119.
2. Balla A, Balla T. 2006. Phospatidylinositol 4-kinases: Old enzymes with emerging functions. Trends Cell Biol 16:351-361.
3. Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang DJ, et al. 2006. The need for speed: An update on methamphetamine addiction. J Psychistr Nurosci 31:301-313.
4. Brown JM, Hanson GR, Fleckenstein AE. 2001. Regulation of the vesicular monoamine transporter-2: A novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther 296:762-767.
5. Carvelli L, Moron JA, Kahlig KM, Ferrer JV, Shen N, et al. 2002. PI3-kinase regulation of dopamine uptake. J Neurochem 81:859-869.
6. Cremona O, De Camilli P. 2001. Phosphoinositides in membrane traffic at the synapse. J Cell Sci 114:1041-1052.
7. Eberhard DA, Cooper CL, Low MG, Holz RW. 1990. Evidence that the inositol phospholipids are necessary for exocytosis. J Biochem 268:15-25.
8. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. 2007. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47:681-698.
9. Goldman D, Oroszi G, Ducci F. 2005. The genetics of addictions: Uncovering the genes. Nat Rev Genet 6:521-532.
10. Hashimoto K. 2007. New research on methamphetamine abuse. In: Toolaney GH, editor. New research on methamphetamine abuse. New York:Nova Science Publishers, Inc. pp 1-51.
11. 2+-activated secretion. Nature 366:572-575.
12. 2+-activated secretion. Nature 374:173-177.
13. He ZD, Li ZQ, Shi YY, Tang W, Huang K, et al. 2007. The PIP5K2A gene and schizophrenia in the Chinese population-A case-control study. Schizophr Res 94:359-365.
14. Ikeda M, Iwata N, Suzuki T, Kitajima T, Yamanouchi Y, et al. 2006. Positive association of AKT1 haplotype to Japanese methamphetamine use disorder. Int J Neuropsychopharmacol 9:77-81.
15. Jungerius BJ, Hoogendoorn ML, Bakker SC, Van't Slot R, Bardoel AF, Ophoff RA, et al. 2007. An association screen of myelin-related genes implicates the chromosome 22q11 PIK4CA gene in schizophrenia. Mol Psychiatry (in press).
16. Kendler KS, Karkowski LM, Neale MC, Prescott CA. 2000. Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiatry 57:261-269.
17. +-dependent mechanism. J Biol Chem 278:12070-12077.
18. Kishimoto M, Ujike H, Motohashi Y, Tanaka Y, Okahisa Y, et al. 2008. The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis. Biol Psychiatry 63:191-196.
19. Kosten TR, Markou A, Koob GF. 1998. Depression and stimulant dependence: Neurobiology and pharmacotherapy. J Nerv Ment Dis 186:737-745.
20. T, Chen C, Hu X, Ball D, Lin SK, et al. 2004. Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am J Med Genet Part B 129B:120-124.
21. Lin Z, Zhang PW, Zhu X, Melgari JM, Huff R, et al. 2003. Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites. J Biol Chem 278:20162-20170.
22. Matsuzawa D, Hashimoto K, Miyatake R, Shirayama Y, Shimizu E, et al. 2007. Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis. Am J Psychiatry 164:1105-1114.
23. Merikangas KR, Stolar M, Stevens DE, Goulet J, Preisig MA, et al. 1998. Familial transmission of substance use disorders. Arch Gen Psychiatry 55:973-979.
24. Saito T, Aghalar MR, Lachman HM. 2005. Analysis of PIK3C3 promoter variant in African-Americans with schizophrenia. Schizophr Res 76:361-362.
25. Sato M, Chen CC, Akiyama K, Otsuki S. 1983. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 18:429-440.
26. Sato M, Numachi Y, Hamamura T. 1992. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull 18:115-122.
27. Schwab SG, Knapp M, Sklar P, Eckstein GN, Sewekow C, et al. 2006. Evidence for association of DNA sequence variations in the phosphatidylinositol- 4-phosphate 5-kinase II alpha gene (PIP5K2A) with schizophrenia. Mol Psychiatry 11:837-846.
28. Snyder SH. 1973. Amphetamine Psychosis: A ''model'' schizophrenia mediated by catecholamines. Am J Psychiatry 130:61-67.
29. Stopkova P, Saito T, Fann CS, Papolos DF, Vevera J, et al. 2003. Polymorphism screening of PIP5K2A, a candidate gene for chromosome 10p-linked psychiatric disorders. Am J Med Genet Part B 123B:50-58.
30. Stopkova P, Saito T, Papolos DF, Vevera J, Paclt I, et al. 2004. Identification of PIK3C3 promoter variant associated with bipolar disorder and schizophrenia. Biol Psychiatry 55:981-988.
31. Sulzer D, Sonders MS, Poulsen NW, Galli A. 2005. Mechanisms of neurotransmitter release by amphetamine: A review. Prog Neurobiol 75:406-433.
32. Tatetsu S. 1963. Methamphetamine psychosis. Folia Psychiatr Neurol Jpn Suppl 7:377-380.
33. Uhl GR, Liu QR, Naiman D. 2002. Substance abuse vulnerability loci: Converging genome scanning data. Trends Genet 18:420-425.
34. Ujike H. 2002. Stimulant-induced psychosis and schizophrenia: The role of sensitization. Curr Psychiatry Rep 4:177-184.
35. Ujike H, Sato M. 2004. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann NY Acad Sci 1025:279-287.
36. Volz TJ, Hanson GR, Fleckenstein AE. 2007. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits. J Neurochem 101:883-888.
37. Wiedemann C, Schafer T, Burger MM. 1996. Chromaffin granule-associated phosphatidylinositol 4-kinase activity is required for stimulated secretion. EMBO J 15:2094-2101.